1. Home
  2. |Insights
  3. |U.S. Access Board Proposes Updates to Section 508 Standards

U.S. Access Board Proposes Updates to Section 508 Standards

Client Alert | less than 1 min read | 02.20.15

On February 18, 2015, the U.S. Access Board published a proposed rule revising and updating the standards implementing Section 508 of the Rehabilitation Act of 1973, as amended, regarding the accessibility of electronic and information technology developed, procured, maintained, or used by federal agencies. Click here for our summary and analysis of this proposed rule.

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...